Following a new diagnosis of IDH-mutant grade 2 astrocytoma, patients have three primary options for postoperative management outside clinical trials: watchful waiting, radiotherapy (RT) combined with chemotherapy, or IDH-targeted therapy. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).